Terms: = Kidney tumors AND TFEB, TCFEB, 7942, ENSG00000112561, P19484, AlphaTFEB AND Diagnosis
56 results:
1. Prognosis and Clinicopathological Characters of Adult tfeb-Altered Renal Cell Carcinoma: A Single Center Experience of 18 Cases.
Wu J; Cao CZ; Cui HL; Du G; Shi HZ; Liang J; Guo L; Wang YC; Zhang J; Zhou AP; Li CL; Zheng S; Shou JZ
Clin Genitourin Cancer; 2024 Apr; 22(2):261-268.e3. PubMed ID: 38104031
[TBL] [Abstract] [Full Text] [Related]
2. Genomic alterations and diagnosis of renal cancer.
Zhang X; Bolck HA; Rupp NJ; Moch H
Virchows Arch; 2024 Feb; 484(2):323-337. PubMed ID: 37999735
[TBL] [Abstract] [Full Text] [Related]
3. Lessons from 801 clinical TFE3/tfeb fluorescence in situ hybridization assays performed on renal cell carcinoma suspicious for MiTF family aberrations.
Wang XM; Shao L; Xiao H; Myers JL; Pantanowitz L; Skala SL; Udager AM; Vaishampayan U; Mannan R; Dhanasekaran SM; Chinnaiyan AM; Betz BL; Brown N; Mehra R
Am J Clin Pathol; 2023 Dec; 160(6):549-554. PubMed ID: 37499055
[TBL] [Abstract] [Full Text] [Related]
4. A
Smith SC; Yu J; Paul AK
Int J Surg Pathol; 2024 May; 32(3):539-542. PubMed ID: 37415407
[TBL] [Abstract] [Full Text] [Related]
5. Metastatic Translocated Renal Cell Carcinoma in a kidney Transplant Patient - a Case Report and Review of the Literature.
Kläger J; Schmidinger M; Oszwald A; Wasinger G; Fajkovic H; Compérat E
Int J Surg Pathol; 2024 May; 32(3):594-600. PubMed ID: 37415400
[No Abstract] [Full Text] [Related]
6. High-throughput and targeted drug screens identify pharmacological candidates against MiT-translocation renal cell carcinoma.
Lang M; Schmidt LS; Wilson KM; Ricketts CJ; Sourbier C; Vocke CD; Wei D; Crooks DR; Yang Y; Gibbs BK; Zhang X; Klumpp-Thomas C; Chen L; Guha R; Ferrer M; McKnight C; Itkin Z; Wangsa D; Wangsa D; James A; Difilippantonio S; Karim B; Morís F; Ried T; Merino MJ; Srinivasan R; Thomas CJ; Linehan WM
J Exp Clin Cancer Res; 2023 Apr; 42(1):99. PubMed ID: 37095531
[TBL] [Abstract] [Full Text] [Related]
7. Low-grade oncocytic tumour (LOT) of the kidney is characterised by GATA3 positivity, FOXI1 negativity and mTOR pathway mutations.
Chen T; Peng Y; Lei T; Wu C; Wang H; Shi Y
Pathol Oncol Res; 2023; 29():1610852. PubMed ID: 36816543
[No Abstract] [Full Text] [Related]
8. MiT/TFE Family Renal Cell Carcinoma.
Tang J; Baba M
Genes (Basel); 2023 Jan; 14(1):. PubMed ID: 36672892
[TBL] [Abstract] [Full Text] [Related]
9. Clear cell renal cell carcinoma with focal psammomatous calcifications: a rare occurrence mimicking translocation carcinoma.
Sangoi AR; Al-Obaidy KI; Cheng L; Kao CS; Chan E; Sadasivan S; Levin AM; Alvarado-Cabrero I; Kunju LP; Mehra R; Mannan R; Wang X; Dhillon J; Tretiakova M; Smith SC; Hes O; Williamson SR
Histopathology; 2023 Apr; 82(5):684-690. PubMed ID: 36564980
[TBL] [Abstract] [Full Text] [Related]
10. tfeb-associated renal cell carcinoma: A case report and literature review.
Zhu Y; Xia C; Ou Y; Zhang C; Li L; Yang D
Medicine (Baltimore); 2022 Dec; 101(50):e31870. PubMed ID: 36550835
[TBL] [Abstract] [Full Text] [Related]
11. New insights in the new WHO classification of adult renal tumors.
Hes O; Michalová K; Pivovarčíková K
Cesk Patol; 2022; 67(4):187-191. PubMed ID: 36513503
[TBL] [Abstract] [Full Text] [Related]
12. TFE3 and tfeb-rearranged renal cell carcinomas: an immunohistochemical panel to differentiate from common renal cell neoplasms.
Caliò A; Marletta S; Brunelli M; Pedron S; Portillo SC; Segala D; Bariani E; Gobbo S; Netto G; Martignoni G
Virchows Arch; 2022 Dec; 481(6):877-891. PubMed ID: 35980471
[TBL] [Abstract] [Full Text] [Related]
13. Merlin immunohistochemistry is useful in diagnosis of tumours within the spectrum of biphasic hyalinizing psammomatous renal cell carcinoma.
Collins K; Hwang M; Antic T; Paintal A; Argani P; Matoso A; Gopinath A; Baskovich B; Mehra R; Williamson SR; Idrees MT; Barletta JA; Anderson WJ; Hirsch MS; Hornick JL; Acosta AM
Histopathology; 2022 Nov; 81(5):577-586. PubMed ID: 35971742
[TBL] [Abstract] [Full Text] [Related]
14. MiTF/TFE Translocation Renal Cell Carcinomas: From Clinical Entities to Molecular Insights.
Simonaggio A; Ambrosetti D; Verkarre V; Auvray M; Oudard S; Vano YA
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35886994
[TBL] [Abstract] [Full Text] [Related]
15. Comprehensive study of nine novel cases of tfeb-amplified renal cell carcinoma: an aggressive tumour with frequent PDL1 expression.
Kammerer-Jacquet SF; Gandon C; Dugay F; Laguerre B; Peyronnet B; Mathieu R; Verhoest G; Bensalah K; Leroy X; Aubert S; Vermaut C; Escande F; Verkarre V; Compérat E; Ambrosetti D; Pedeutour F; Belaud-Rotureau MA; Rioux-Leclercq N;
Histopathology; 2022 Aug; 81(2):228-238. PubMed ID: 35562857
[TBL] [Abstract] [Full Text] [Related]
16. Eosinophilic solid and cystic renal cell carcinoma and renal cell carcinomas with tfeb alterations: a comparative study.
Lobo J; Rechsteiner M; Helmchen BM; Rupp NJ; Weber A; Moch H
Histopathology; 2022 Jul; 81(1):32-43. PubMed ID: 35403742
[TBL] [Abstract] [Full Text] [Related]
17. Renal cell carcinoma in children and adolescents: a retrospective study of a French-Italian series of 93 cases.
Denize T; Massa S; Valent A; Militti L; Bertolotti A; Barisella M; Rioux-Leclercq N; Malouf GG; Spreafico F; Verschuur A; van der Beek J; Tytgat L; van den Heuvel-Eibrink MM; Vujanic G; Collini P; Coulomb A
Histopathology; 2022 May; 80(6):928-945. PubMed ID: 35238063
[TBL] [Abstract] [Full Text] [Related]
18. Immunohistochemistry for the diagnosis of renal epithelial neoplasms.
Akgul M; Williamson SR
Semin Diagn Pathol; 2022 Jan; 39(1):1-16. PubMed ID: 34823973
[TBL] [Abstract] [Full Text] [Related]
19. Diagnostic utility of one-stop fusion gene panel to detect TFE3/tfeb gene rearrangement and amplification in renal cell carcinomas.
Harada S; Caliò A; Janowski KM; Morlote D; Rodriguez Pena MD; Canete-Portillo S; Harbi D; DeFrank G; Magi-Galluzzi C; Netto GJ; Martignoni G; Mackinnon AC
Mod Pathol; 2021 Nov; 34(11):2055-2063. PubMed ID: 34148064
[TBL] [Abstract] [Full Text] [Related]
20. tumors masquerading as type 2 papillary renal cell carcinoma: pathologists' ever-expanding differential diagnosis for a heterogeneous group of entities.
Taylor AS; Skala SL
Urol Oncol; 2022 Dec; 40(12):499-511. PubMed ID: 34116938
[TBL] [Abstract] [Full Text] [Related]
[Next]
